|
CHIC2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.54309898192651E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.82949999594229E-08 |
| Normal-vs-Stage2 |
2.53860000021255E-07 |
| Normal-vs-Stage3 |
7.21379622703466E-11 |
| Normal-vs-Stage4 |
8.85500006653217E-10 |
| Stage1-vs-Stage2 |
6.397600E-02 |
| Stage1-vs-Stage3 |
1.345780E-02 |
| Stage1-vs-Stage4 |
9.099900E-03 |
| Stage2-vs-Stage3 |
9.434200E-01 |
| Stage2-vs-Stage4 |
6.273000E-01 |
| Stage3-vs-Stage4 |
4.893400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.1371021859743E-11 |
| Normal-vs-AfricanAmerican |
1.047500E-04 |
| Normal-vs-Asian |
1.15389999999493E-06 |
| Caucasian-vs-AfricanAmerican |
7.537800E-01 |
| Caucasian-vs-Asian |
8.832000E-01 |
| AfricanAmerican-vs-Asian |
8.544200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.32790026039243E-10 |
| Normal-vs-Female |
1.6732004670672E-10 |
| Male-vs-Female |
4.088800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.04369999975873E-07 |
| Normal-vs-Age(41-60Yrs) |
8.00309996051851E-09 |
| Normal-vs-Age(61-80Yrs) |
2.57394106029096E-12 |
| Normal-vs-Age(81-100Yrs) |
6.997500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.019630E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.73309999995652E-06 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.838800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.982320E-03 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.119800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.609600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.76870999999412E-05 |
| Classical-VS-Follicular |
3.064300E-03 |
| Classical-VS-Other |
3.782400E-01 |
| Classical-VS-Normal |
7.61800000859125E-09 |
| Tall-VS-Follicular |
1.835810E-01 |
| Tall-VS-Other |
9.152100E-02 |
| Tall-VS-Normal |
1.66829883241348E-11 |
| Follicular-VS-Other |
1.048380E-01 |
| Follicular-VS-Normal |
1.50010004418277E-09 |
| Other-VS-Normal |
2.214800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.83249970753252E-10 |
| Normal-vs-N1 |
1.85779999994917E-06 |
| N0-vs-N1 |
4.048800E-01 |
|
|
